The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy “In a healthcare system where affordability too often dictates ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
On the heels of an FDA label expansion in August, Amgen is touting another potential avenue to extend the value of its decade-old PCSK9 cholesterol med Repatha. In the late-stage Vesalius-CV study, ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback